A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19

NCT04672395 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

31454

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: CpG 1018/Alum-adjuvanted SCB-2019 vaccine
BIOLOGICAL: Placebo; 0.9% saline
BIOLOGICAL: SCB-2019 vaccine
BIOLOGICAL: SCB-2019 vaccine for Placebo

Sponsor

Clover Biopharmaceuticals AUS Pty

Collaborators

[object Object]
[object Object]